Can mindfulness-based cognitive therapy (a group self-help program) improve the quality of life for inflammatory bowel disease patients?

The use of mindfulness-based cognitive therapy for improving quality of life for inflammatory bowel disease patients: a pilot randomised controlled trial with embedded process evaluation

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN27934462

Enrollment

Registered

2013-08-09

Start date

2013-05-01

Completion date

Unknown

Last updated

2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory bowel disease Digestive System Noninfective enteritis and colitis

Interventions

There are two arms to this study: an active intervention group (8-week mindfulness-based cognitive therapy group) and a waiting list control group The mindfulness-based cognitive therapy involves eig

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Be able to verbally communicate and write in English (English language does not have to be first language) 2. Able to give informed consent 3. Age of 18 or over (no upper limit) 4. Confirmed diagnosis of Crohn's disease or Ulcerative Colitis (by clinician) 5. Ability to do light exercise (for example to lift arms above the head or bend knees) 6. To be able to commit to at least 6 sessions out of 8 7. To be able to commit to do home practice of up to 45 minutes daily over the 8 weeks of the study 8. No change of antidepressants (dose or type) within the last three months

Exclusion criteria

Exclusion criteria: 1. Unable to give informed consent 2. Major psychiatric illness 3. Active alcohol or drug dependency 4. Scheduled for major surgery in the next three months 5. Participation in pharmacological study or psychological intervention study within the last six months or intention to participate in pharmacological study during the duration of this study 6. Have recently (within the last three months) been prescribed antidepressants 7. With exacerbated symptoms

Design outcomes

Primary

Measure	Time frame
Quality of life - IBDQ inflammatory bowel disease specific quality of life questionnaire at baseline, two months and six months follow up.	—

Secondary

Measure	Time frame
1. Anxiety - state and trait anxiety (STAI) 2. Depression - Becks depression inventory (BDI) 3. Disease activity - Crohn's disease activity Index - (CDAI) or Simple clinical colitis activity index (SCCAI) 4. Attention Awareness - Mindful attention awareness scale (MAAS) All assessed at baseline, two months and six months follow up Evaluation Survey at two months	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 21, 2026